This video promotes it, but we haven’t matched it to a product page yet, so there are no product figures.
The video leverages the high public interest in weight loss drugs by discussing a new, potentially more effective experimental drug. It uses clear comparisons to familiar medications and highlights significant weight loss figures, creating intrigue and a sense of breakthrough.
This video discusses Retatrutide, an experimental weight loss drug developed by Lilly. It highlights the drug's significant weight loss results in clinical trials, comparing it to existing medications like Ozempic and Wegovy. The segment also touches on eligibility criteria, potential side effects, and the recent announcement of an expanded access pathway for the drug.
Access to experimental weight loss drug
Introduction to Retatrutide and its weight loss potential
Comparison with existing weight loss drugs (Ozempic, Wegovy, Zepbound)
Explanation of Retatrutide's mechanism (triple hormone pathway)
Discussion of eligibility and target patient population
Overview of clinical trial results and potential benefits
Mention of side effects and the new expanded access pathway
R-10 (drug vial): Appears as a visual aid, does not act. Removing it would not change the video. Lilly (company logo): Appears on a table graphic and on a drug criteria graphic. Does not act. Removing it would not change the video. Retatrutide (drug name): Mentioned and shown on graphics. It is the subject of the video. Removing it would fundamentally change the video. Ozempic (drug name): Mentioned as a comparison point. Does not act. Removing it would not change the video. Wegoovy (drug name): Mentioned as a comparison point. Does not act. Removing it would not change the video. Zepbound (drug name): Mentioned as a comparison point. Does not act. Removing it would not change the video.

Playing this video’s own audio, so you’ll hear the creator over the sound.
Promotes 4 products. Create free account to see more.
Outliers and viral hits: their videos on Overshot, all time.